MD Anderson and UT Austin Create Unique Data-Driven Collaboration to Eliminate Cancer Using Novel Mathematical and Computational Approaches
The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center (TACC) – today announced a new...
24-Jun-2020 2:55 PM EDT Add to Favorites
In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas MD Anderson Cancer Center found that greater inactivity was independently associated with a higher risk of dying...
18-Jun-2020 1:25 PM EDT Add to Favorites
Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer
A combination of two biomarkers was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors in patients with advanced bladder cancers.
15-Jun-2020 5:25 PM EDT Add to Favorites
MD Anderson and Philips collaborate to facilitate personalized oncology treatments and clinical trial matching based on genomic markers
MD Anderson and Philips today announced a collaboration to aid oncologists around the world to personalize therapy based on their patients' genomic profiles, with the aim of improving patient care.
16-Jun-2020 9:15 AM EDT Add to Favorites
MD Anderson and Rakuten Medical announce strategic alliance to advance Illuminox platform for cancer treatments
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical’s proprietary IlluminoxTM...
4-Jun-2020 9:40 AM EDT Add to Favorites
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of...
29-May-2020 10:30 AM EDT Add to Favorites
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers...
29-May-2020 10:20 AM EDT Add to Favorites
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck...
29-May-2020 10:05 AM EDT Add to Favorites
See All News
Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer
In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT
It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT
Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT
A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT
MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT
Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST
30-Oct-2013 8:10 PM EDT
30-Oct-2013 8:00 PM EDTSee All Experts